法蒂玛的故事：针对IV期肺癌的CIMAvax-EGF®免疫疗法
在完成IV期非小细胞肺癌的一线化疗后，法蒂玛前往古巴接受CIMAvax-EGF®免疫疗法。整合肿瘤学项目支持了她的康复和生活质量。
"我在拉普拉德拉接受的护理超越了医疗治疗。他们给了我希望，在整个住院期间以尊严对待我。"
— Fatima H., Turkey
The Diagnosis
Fatima, a 54-year-old teacher from Istanbul, was diagnosed with stage IV non-small-cell lung cancer (adenocarcinoma). After completing first-line chemotherapy, her oncologist discussed the option of Cuban immunotherapy vaccines. The family researched CIMAvax-EGF® and contacted La Pradera's international patient services.
Medical Review and Eligibility
Fatima's complete medical records — including pathology reports, CT scans, and treatment history — were reviewed by La Pradera's integrative oncology team. They confirmed she was eligible for CIMAvax-EGF® therapy, as she had completed first-line chemotherapy and met the treatment criteria.
The Treatment Journey
Fatima and her husband traveled to Havana for a 42-day treatment program. The protocol included CIMAvax-EGF® injections, nutritional oncology support, psychological counseling, and quality-of-life therapies. The integrative approach focused on supporting her immune system while managing treatment side effects.
Supportive Care
Beyond the immunotherapy, Fatima received comprehensive supportive care — pain management, nutritional counseling tailored to her needs, and psychological support. The multilingual team included a Turkish-speaking coordinator who ensured clear communication throughout.
Return Home and Coordination
Fatima returned to Istanbul with a detailed treatment summary that was shared with her home oncologist. The La Pradera team remains in contact with her family for follow-up coordination. Fatima reports improved quality of life and continues to be monitored by her oncologist in Turkey.
我们使用 Cookie 来改善您的体验并分析流量。继续使用即表示您同意我们使用 Cookie。 隐私政策